NASDAQ:ELUT Elutia Q1 2026 Earnings Report $1.00 +0.03 (+2.70%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Elutia EPS ResultsActual EPSN/AConsensus EPS -$0.15Beat/MissN/AOne Year Ago EPSN/AElutia Revenue ResultsActual RevenueN/AExpected Revenue$3.00 millionBeat/MissN/AYoY Revenue GrowthN/AElutia Announcement DetailsQuarterQ1 2026Date5/14/2026TimeAfter Market ClosesConference Call DateThursday, May 14, 2026Conference Call Time5:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Elutia Earnings HeadlinesElutia to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026April 30, 2026 | globenewswire.comElutia Insider Trading Activity | NASDAQ:ELUT | BenzingaApril 5, 2026 | benzinga.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.May 6 at 1:00 AM | Brownstone Research (Ad)Elutia (ELUT) price target increased by 42.86% to 5.10March 29, 2026 | msn.comElutia to Present at Sidoti’s Small-Cap Virtual Investor Conference March 18-19March 17, 2026 | markets.businessinsider.comElutia to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19March 17, 2026 | globenewswire.comSee More Elutia Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Elutia? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Elutia and other key companies, straight to your email. Email Address About ElutiaElutia (NASDAQ:ELUT), Inc. is a biopharmaceutical company focused on the development of novel nitric oxide therapies based on its proprietary polymeric nitric oxide platform. This technology is designed to enable sustained, controlled release of nitric oxide to targeted tissues, potentially overcoming the delivery challenges associated with gaseous nitric oxide and small‐molecule donors. The company’s lead program is in preclinical development for pulmonary arterial hypertension, with additional research efforts aimed at other cardiovascular and respiratory conditions. Elutia’s platform may also have applications in acute respiratory distress and inflammatory diseases, and the company continues to explore partnerships to expand its pipeline and accelerate development timelines. Founded in 2015 and headquartered in New Haven, Connecticut, Elutia serves the U.S. market and is pursuing collaborations to support international expansion. Its management team brings together expertise in biopharmaceutical research, clinical development, and regulatory affairs, with a shared focus on advancing innovative therapies toward regulatory approval and commercialization.View Elutia ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Years in the Making, AMD’s Upside Movement Has Just BegunOld Money, New Tech: Western Union's Crypto RebootPinterest Pins a Profit Play To Its Mood BoardJust How Big a Problem Could Amazon’s Cash Burn Rate Be?BlackBerry Rewrites Its Own Operating SystemGrab Holdings Faces Hurdles, But Upside Potential Is Hard to IgnorePalantir Drops After a Blowout Q1—What Investors Should Know Upcoming Earnings Coinbase Global (5/7/2026)Airbnb (5/7/2026)Datadog (5/7/2026)Ferrovial (5/7/2026)Gilead Sciences (5/7/2026)Microchip Technology (5/7/2026)MercadoLibre (5/7/2026)Monster Beverage (5/7/2026)Canadian Natural Resources (5/7/2026)W.W. Grainger (5/7/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
